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Abstract 
Internal audit plays an increasingly important role in the field of management. In today's economic environment, 
means and methods to achieve high financial performance in the medium and long-term perspective are purposefully 
sought.  
In the new reality, practice puts an emphasis on the need for additional control on the activities which, in turn, 
justifies concrete changes in the policy of the organizations as well. In terms of the individual organization, the 
implementation of internal audit is a set of applications of international practices and compliance with the national 
legislation that are undertaken to improve the competitiveness.  
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Introduction 
The historical origin of the audit is linked to the birth of statehood and the accompanying government control 
on the activities and the accountability of organizations. Its participation has been limited to verification and prevention 
of accounting errors and compliance with the tax regime.  
The need of an internal audit is associated with an increase in the size of the organization and the scope of its 
activities. Since 19 century, organizations have created more complex structures with widely dispersed geographic 
locations. The limited ability of the management to monitor all structural units and business activities has led to 
constituting the internal auditing as a monitoring function.  
 
With the expansion of production and distribution of medicinal products beyond the national borders, in 1967 the 
internal audit was separated as an activity from the external audit1. In the "Good Manufacturing Practice" of the World 
Health Organization, the internal audit is presented as part of the quality control of medicinal products. Considering the 
social and economic significance of the pharmaceutical sector, most countries adopt national policies for medicinal 
products according to which the manufacturers are required to adopt a quality assurance system, including an internal 
audit. Manufacturers of medicinal products have the right to exercise control over suppliers of raw materials and over 
distributors, and to this end, the latter create new structural internal audit units.  
 
For historical and legislative reasons, the internal audit is not yet a subject of the academic periodicals2. The 
functions of the audit for the organization and for the society determine the literature as regulation interpretative. Due to 
the different stages of development of the national economy and the lack of a uniform structure of the individual 
organizations, the literature is limited to manuals from international organizations and national laws and with a 
small focus on empirical data. The study of the internal audit is a field wider than its nature, as defined by the Institute 
of Internal Auditors3.  
 
Approximation of International Good Practices in Internal Audit  
The process of globalization puts on the agenda the product quality issue. To occupy competitive positions on the 
international market, organizations are beginning to use a new management tool – internal audit. Its separation from 
the external audit is accompanied by scientific debate and governmental support. The scope of internal audit is 
expanding, as the traditional function of control over accounting is complemented with new fields, such as verification 
of the financial management and quality management. The internal audit begins to provide a service for the 
management.  
 
As the beginning of the process of approximation of the internal audit policies is to be accepted the crisis in 2002 
in USA (Enron, WorldCom). Violations of accounting standards and the lack of good audit practices create regulatory 
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requirements for the building and the efficient functioning of good internal audit practices on a world scale4.  
Approximation of international policies on internal audit is carried out in three different directions:  
- Being the result of the processes in international economic relations, the policies on quality in the various 
regions of the world have marked convergence. The internal audit in the pharmaceutical sector expands its field of 
action to include control of the quality system. In the "Pharmaceutical Quality System Guidance" (ICH Q10), adopted 
in the EU, Japan and the US, the quality system requirements provide a "feedback on the quality of the production of 
internal and external sources, non-conformity of the established parameters, discontinued sales, deviation from 
standards, results of auditors and inspections by regulatory authorities". In the EU, self-inspection is part of the quality 
system, while in the US and Great Britain the broader term is used - "internal audit".  
- The approximation of accounting standards determines the convergence of the auditing standards. The 
Norwalk Agreement of 2002 between the International Accounting Standards Board and the US Financial Accounting 
Standards Board provides for integration of the accounting standards. Additional trend is approximation of the audit 
practices in order to ensure that the financial reports comply with the International Accounting Standards.  
- Globalization of organizational assets and capital markets places on the international community's agenda the 
debate on the various practices in risk management. On expanding their activities abroad, pharmaceutical 
organizations are beginning to apply similar criteria in accordance with the national requirements. The control of risk 
management, as part of the scope of the internal audit, is applied under the "bottom-up" scheme - good practices of 
leading organizations are recorded by the supervisory authorities and are adopted by the remaining organizations.  
 
Regardless of the approximation process, policies on internal audit should consider in perspective the general 
problem of the structural control departments (internal audit, risk management, IT risk) which are located in the middle 
management level of the organization. Typically for the approximation of the international practices, the internal audit 
finds the balance between the requirements of the supervisory authorities and the expectations to add value to the 
organization. The internal audit must be functionally separated from the daily management, but also to provide 
opportunity for the top management to ensure that their recommendations have corrective action.  
 
The contemporary practice solves the issue by diversifying the internal audit teams. Their composition is 
intersectoral and interfunctional, and includes experts in accounting, finance, risk management, information technology, 
and investment.  
 
EU Common Practices  
The EU policy in respect of the medicinal products is protection of the interests of the citizens and the 
economy. The system for admission to the market must ensure that all medicinal products are evaluated by a competent 
authority for compliance with the requirements for safety, quality, and efficiency. One of the tools of the system is 
carrying out an internal audit.  
The EU internal audit practices originate from the Euro Model for Excellent (EFQM Excellence Model). It was 
adopted in 1991 in response to changes in the external environment and most of all due to the increased competition of 
the United States and Japan. The Euro Model establishes a framework for evaluation and improvement of the European 
organizations for competitiveness.  
Individual states are beginning to apply internal audit in their national legislation. Good practices for the EU 
include the two main stages of the pharmaceutical sector: Production (Directive 91/356/EEC on the principles and 
guidelines of good manufacturing practice for medicinal products for human use) and distribution (Directive 92/25/EEC 
on the wholesale distribution of medicinal products for human use).  
The process of harmonization in the EU provides regulation of good practices in production, while distribution 
practices remain priority of the manufacturers themselves. The contemporary EU policy is laid down in the 
"Guidelines on Good Manufacturing Practice"5 of the European Commission.  
 
Good Practices in Bulgaria  
With the adoption of the market principles and the fall of the state monopoly in the pharmaceutical sector, 
the international good practices for the production and distribution of medicinal products have begun to apply in 
Bulgaria. The scope of activity of the internal audit is expanding, as the traditional accounting activity is complemented 
by quality management.  
In 1995, the first law regulating the pharmaceutical sector was passed - the Law on Medicines and Pharmacies in 
Human Medicine. Its 2000 amendment reviews solely the good manufacturing practice as a system of rules which 
covers all aspects of production.  
 
 
                                                 
4
 Institute of Internal Auditors. The role of the internal control and the function of the internal audit for the effective 
management and organic growth of the organizations. 2006. 
5
 European Commission. Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for 
human use. 
15 
 
Since 2001, through the "Good manufacturing practice of medicines", the requirements of the World Health 
Organization have been applied (Ordinance No. 12 of 03.26.2001 for the establishment of the good manufacturing 
practice of medicines, the State Gazette, issue 47, 2001). In accordance with the European practice, the internal audit is 
considered as "self-inspection".  
Since 2007, Ordinance No 39 has reviewed the good distribution practice as part of the quality system which 
ensures adequate control at all stages of the process of wholesale trade in medicinal products. At the root of the good 
distribution practice lies the principle for sharing the responsibility for quality and safety of medicinal products. The 
Ordinance envisages the legal opportunity and obligation to carry out audits in the own organization, as well as in that 
of the suppliers and distributors. Responsibility for conducting the audit is shared between manufacturer, supplier and 
distributor, i.e. the manufacturer has the legal opportunity to carry out internal audits of suppliers and distributors from 
the time of receipt of the authorization for production, and on a periodic basis.  
In 2009, Ordinance No 15 introduced the provisions of Directive 2003/94/EC on good manufacturing practices. 
The good manufacturing practice for medicinal products is subject to the principles of sharing the responsibility for the 
quality, safety and efficacy of medicinal products. The internal audit is specified in an amendment to the Ordinance of 
2013, as the manufacturers of medicinal products have been assigned with the responsibility to establish and maintain a 
department of quality control functioning under the management of a person who has the requisite classification and is 
independent from the production. The manufacturer is obliged to conduct periodic self-inspections and control within 
the framework of the quality assurance system for the purposes of monitoring the application of the principles of good 
manufacturing practices and the implementation of the necessary corrective measures.  
 
A tendency towards changes in the scope exists in the contemporary Bulgarian practice of internal audit6. The 
focus of work is expected to shift to audits of processes and in particular to corporate governance, information 
technology, risk management, and ethics. The role of internal audit reports a change towards increasing the role of the 
internal audit in relation to the risk management in the company.  
 
Conclusion  
In the modern economy, there is a trend towards introducing new tools to the management, and also using 
traditional tools in a new way. The internal audit is exactly such a tool: for countries with established market 
economy, it is a traditional tool with a new application, while for Bulgaria it is a new tool. The effects of the global 
crisis and the requirements of the European directives determine the internal audit as one of the main tools of the 
management for competitiveness and economic growth.  
 
The specifics of internal audit are determined by the processes in the world economy. A key factor in 
determining the practice of internal auditing is the globalization. To increase the competitiveness, the internal audit 
becomes a mandatory element in the organizations introduced by the good practices. The current internal audit practices 
are being influenced mainly by processes at three separate levels: international, pan-European and national level.  
The approximation of international internal audit policies is carried out in accordance with definitions and 
recommendations of international organizations. The process of globalization creates requirements for control of the 
quality system, approximation of audit standards in parallel with approximation of accounting standards and risk 
management.  
Harmonization of the internal audit rules in the EU stems in a regulatory order harmonized with the 
recommendations of the international specialized organizations. Directives are used to establish the institutional 
framework for competitiveness and a single definition for independence of auditors.  
The Bulgarian practice follows the dynamics of European trends. With the accession of Bulgaria to the EU, the 
internal audit units were created. The Directives are applied through the "Good Manufacturing Practice" Standard.  
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